相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis
Tanuja N. Gengiah et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants
Emily R. Holzinger et al.
PHARMACOGENETICS AND GENOMICS (2012)
Paradoxically elevated efavirenz concentrations in HIV/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy
Awewura Kwara et al.
AIDS (2011)
The SLCO1B1 rs4149032 Polymorphism Is Highly Prevalent in South Africans and Is Associated with Reduced Rifampin Concentrations: Dosing Implications
Emmanuel Chigutsa et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Effect of Rifampicin and CYP2B6 Genotype on Long-Term Efavirenz Autoinduction and Plasma Exposure in HIV Patients With or Without Tuberculosis
E. Ngaimisi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Serum nevirapine and efavirenz concentrations and effect of concomitant rifampicin in HIV infected children on antiretroviral therapy
Ira Shah et al.
INDIAN PEDIATRICS (2011)
Tuberculosis in human immunodeficiency virus infected Ugandan children starting on antiretroviral therapy
S. Bakeera-Kitaka et al.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2011)
Pediatric Underdosing of Efavirenz: A Pharmacokinetic Study in Uganda
Quirine Fillekes et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2011)
Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens
Christoph Wyen et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2011)
Primary Isoniazid Prophylaxis against Tuberculosis in HIV-Exposed Children
Shabir A. Madhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Multiple imputation using chained equations: Issues and guidance for practice
Ian R. White et al.
STATISTICS IN MEDICINE (2011)
Efavirenz Primary and Secondary Metabolism In Vitro and In Vivo: Identification of Novel Metabolic Pathways and Cytochrome P450 2A6 as the Principal Catalyst of Efavirenz 7-Hydroxylation
Evan T. Ogburn et al.
DRUG METABOLISM AND DISPOSITION (2010)
Effect of CYP2B6, ABCB1, and CYP3A5 Polymorphisms on Efavirenz Pharmacokinetics and Treatment Response: An AIDS Clinical Trials Group Study
Heather J. Ribaudo et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults
Sumonmal Uttayamakul et al.
AIDS RESEARCH AND THERAPY (2010)
Is the Recommended Dose of Efavirenz Optimal in Young West African Human Immunodeficiency Virus-Infected Children?
Deborah Hirt et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Glucuronidation of the Antiretroviral Drug Efavirenz by UGT2B7 and an in Vitro Investigation of Drug-Drug Interaction with Zidovudine
Anne-Sophie Belanger et al.
DRUG METABOLISM AND DISPOSITION (2009)
Effect of Rifampicin on Efavirenz Pharmacokinetics in HIV-Infected Children With Tuberculosis
Yuan Ren et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2009)
Association of high T allele frequency of CYP2B6 G516T polymorphism among ethnic south Indian HIV-infected patients with elevated plasma efavirenz and nevirapine
Geetha Ramachandran et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
CYP2B6 Variants and Plasma Efavirenz Concentrations during Antiretroviral Therapy in Port-au-Prince, Haiti
Paul Leger et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function
Julia di Iulio et al.
PHARMACOGENETICS AND GENOMICS (2009)
High prevalence of subtherapeutic plasma concentrations of efavirenz in children
Yuan Ren et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2007)
Isoniazid is a mechanism-based inhibitor of cytochrome P-450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes
X Wen et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2002)
Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients
C Marzolini et al.
AIDS (2001)
分享论文
